Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That’s the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a “kinder, gentler” form of allogeneic (donor cell) stem cell transplantation developed at Fred Hutchinson Cancer Research Center. The findings are published Nov. 2 in JAMA, The Journal of the American Medical Association.
“Age is no longer a barrier to allogeneic transplant,” said Mohamed Sorror,
Genetic mutations are commonly studied because of links to diseases such as cancer; however, little is known about mutations occurring in healthy individuals. In a study published online in Genome Research, researchers detected over 400 mutations in healthy blood cells of a 115-year-old woman, suggesting that lesions at these sites are largely harmless over the course of a lifetime.
Our blood is continually replenished by hematopoietic stem cells that reside in the bone marrow and divide to generate different types of blood cells, including white blood cells. Cell division, however, is error-prone, and more frequently dividing cells, including the blood,
Mandi Schwartz ’11 completed a crucial step in her battle with leukemia Wednesday afternoon.
The women’s hockey player received a long-awaited stem cell transplant at about 3:30 p.m. local time at the inpatient transplant unit of the Seattle Cancer Care Alliance at the University of Washington Medical Center. The procedure took 32 minutes and there were no complications, said Dean Forbes, a spokesman for the cancer center.
Schwartz, a native of Saskatchewan, Canada has been in and out of chemotherapy for more than 20 months since first being diagnosed with acute myeloid leukemia in December 2008. After months of searching for
A 41-site clinical trial, testing the restorative effect that adult bone marrow stem cells have on damaged or injured myocardium in heart attack patients, is being led at Wake Forest Baptist by Sanjay Gandhi, MD.
Phase I of the research study found that stem cells derived from bone marrow (mesenchymal stem cells) were safe for patients and may have the ability to limit scar formation, improve heart function and preserve tissue following a first heart attack.
Phase I was a multicenter study of 53 patients which demonstrated that the treatment was safe in adults, and those patients given this
(…) Participation in this drive and thus registration with the National Marrow Donor Program consists of simple swabs of the cheeks using Q-tips for a DNA test. DNA information is entered into this lifesaving donor program database. If a potential donor is identified as a potential match for David or someone else in need, he/she will be contacted by the donor program to have a small amount of blood drawn for lab testing.
If that person is then confirmed as a match, he/she will be asked to provide stem cells through a simple donation procedure where blood is taken